After trimming its cell therapy pipeline last year, the group is now out entirely.

Boehringer discontinues brigimadlin while others continue to struggle.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.

A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.